Evidence map›Paper›PMID 29322280›Full record

ReviewHeart failure reviews2018

Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.

Abdullah Kaplan, Emna Abidi, Ahmed El-Yazbi, Ali Eid, George W Booz, Fouad A Zouein

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 6 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 6 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Empagliflozin treatment rescues abnormally reduced NaAmerican journal of physiology. Heart and circulatory physiology · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 4 countries.

Abdullah KaplanDepartment of Pharmacology and Toxicology, American University of Beirut & Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon.
Emna AbidiDepartment of Pharmacology and Toxicology, American University of Beirut & Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon.
Ahmed El-YazbiDepartment of Pharmacology and Toxicology, American University of Beirut & Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon.
Ali EidDepartment of Pharmacology and Toxicology, American University of Beirut & Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon.
George W BoozDepartment of Pharmacology and Toxicology, University of Mississippi Medical Center, School of Medicine, Jackson, MS, USA.
Fouad A ZoueinDepartment of Pharmacology and Toxicology, American University of Beirut & Medical Center, Riad El-Solh, Beirut, 1107 2020, Lebanon. fouadzouein@outlook.com.
American University of Beirut · LBUniversity of Mississippi Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a global epidemic and a leading cause of death with more than 422 million patients worldwide out of whom around 392 million alone suffer from type 2 diabetes (T2D). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel and effective drugs in managing glycemia of T2D patients. These inhibitors gained recent clinical and basic research attention due to their clinically observed cardiovascular protective effects. Although interest in the study of various SGLT isoforms and the effect of their inhibition on cardiovascular function extends over the past 20 years, an explanation of the effects observed clinically based on available experimental data is not forthcoming. The remarkable reduction in cardiovascular (CV) mortality (38%), major CV events (14%), hospitalization for heart failure (35%), and death from any cause (32%) observed over a period of 2.6 years in patients with T2D and high CV risk in the EMPA-REG OUTCOME trial involving the SGLT2 inhibitor empagliflozin (Empa) have raised the possibility that potential novel, more specific mechanisms of SGLT2 inhibition synergize with the known modest systemic improvements, such as glycemic, body weight, diuresis, and blood pressure control. Multiple studies investigated the direct impact of SGLT2i on the cardiovascular system with limited findings and the pathophysiological role of SGLTs in the heart. The direct impact of SGLT2i on cardiac homeostasis remains controversial, especially that SGLT1 isoform is the only form expressed in the capillaries and myocardium of human and rodent hearts. The direct impact of SGLT2i on the cardiovascular system along with potential lines of future research is summarized in this review.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Global HealthHeart FailureHumansMorbidityPrognosisSodium-Glucose Transporter 2 InhibitorsBlood GlucoseSodium-Glucose Transporter 2 InhibitorsCardiovascularDiabetic cardiomyopathyEMPA-REG OUTCOMESGLT2 inhibitorsType 2 diabetes

Identifiers

PMID29322280
OpenAlexW2782992901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.